Ballentine Partners LLC Buys Shares of 23,035 ProQR Therapeutics (NASDAQ:PRQR)

Ballentine Partners LLC bought a new position in ProQR Therapeutics (NASDAQ:PRQR) during the 4th quarter, Holdings Channel reports. The institutional investor bought 23,035 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other large investors also recently modified their holdings of PRQR. Privium Fund Management B.V. increased its stake in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Finally, OneDigital Investment Advisors LLC increased its stake in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $2.16 on Monday. The firm’s 50 day simple moving average is $2.93 and its 200-day simple moving average is $2.56. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The stock has a market capitalization of $176.43 million, a price-to-earnings ratio of -6.75 and a beta of 0.30.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The firm had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $4.75 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. Analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PRQR shares. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $6.00 to $14.00 in a report on Tuesday, October 29th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, JMP Securities reissued a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).